GenSight Biologics S.A. (SIGHT) Flags Going-Concern Risk; H1 Net Loss €10.3M

GenSight Biologics S.A. reported H1 2026 net loss of €10.3M, cash €1.7M at June 30, and a material going-concern uncertainty. It collected €6.5M cash from early access despite €(1.2)M reported revenue due to rebates and a non-cash accounting change.Material DetailsContext by AI AnalystThis is a mid…